• Publications
  • Influence
Proposal for a New Tool to Evaluate Drug Interaction Cases
The assessment of causation for a potential drug interaction requires thoughtful consideration of the properties of both the object and precipitant drugs, patient-specific factors, and the possibleExpand
  • 447
  • 22
  • PDF
Toward a complete dataset of drug-drug interaction information from publicly available sources
TLDR
A comprehensive dataset of all publically available sources of PDDI information that could be identified using a comprehensive and broad search were combined into a single dataset. Expand
  • 90
  • 10
The proton-pump inhibitors: similarities and differences.
  • J. Horn
  • Medicine
  • Clinical therapeutics
  • 1 March 2000
OBJECTIVE This paper examines the clinical pharmacology of the proton-pump inhibitors (PPIs) and briefly reviews some comparative studies of these agents. BACKGROUND PPIs have emerged as theExpand
  • 214
  • 8
Drug interactions analysis and management
'Drug Interactions Analysis and Management 2014' assists in the prevention and management of drug interactions. Emphasizing management options for improved patient outcomes, the text also andExpand
  • 91
  • 6
Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and gamma-hydroxybutyrate.
Human immunodeficiency virus 1 (HIV-1) protease inhibitors have dramatically reduced the morbidity and mortality due to HIV-1 infection. However, most of these antiretrovirals are also potentExpand
  • 114
  • 5
  • PDF
Review article: relationship between the metabolism and efficacy of proton pump inhibitors – focus on rabeprazole
  • J. Horn
  • Medicine
  • Alimentary pharmacology & therapeutics
  • 1 November 2004
Proton pump inhibitors are now considered the mainstay of treatment for acid‐related disease. Although all proton pump inhibitors are highly effective, the antisecretory effects of different drugs inExpand
  • 66
  • 5
The risk of hypotension following co-prescription of macrolide antibiotics and calcium-channel blockers
Background The macrolide antibiotics clarithromycin and erythromycin may potentiate calcium-channel blockers by inhibiting cytochrome P450 isoenzyme 3A4. However, this potential drug interaction isExpand
  • 63
  • 4
The Better Understanding and Recognition of the Disconnects, Experiences, and Needs of Patients with Chronic Idiopathic Constipation (BURDEN-CIC) Study: Results of an Online Questionnaire
AbstractIntroduction There is limited literature comparing the experiences and attitudes of patients with chronic idiopathic constipation (CIC) to those of healthcare professionals (HCPs) treatingExpand
  • 16
  • 4
Managing Clinically Important Drug Interactions
This handy book provides brief descriptions of clinically important drug interactions selected from the authoritative looseleaf reference, "Drug Interactions Analysis and Management". Only level 1Expand
  • 19
  • 3
  • PDF
Review article: similarities and differences among delayed‐release proton‐pump inhibitor formulations
  • J. Horn, C. Howden
  • Medicine, Chemistry
  • Alimentary pharmacology & therapeutics
  • 23 November 2005
Proton‐pump inhibitors are acid‐labile, and require an enteric coating to protect them from degradation in the stomach when given orally. However, this leads to delayed absorption and onset of actionExpand
  • 61
  • 2